Robert K. Dixon of The World Bank Group, Dixon was Team Leader for Climate Change and Chemicals (2008 to 2015), overseeing a multibillion-dollar portfolio of energy, environment, public health, infrastructure, and transportation projects in developing and transition countries. Dixon has been a delegate to intergovernmental negotiating committees and subsidiary bodies of the United Nations Framework Convention on Climate Change (1992 to present), Montreal Protocol on Substances that Deplete the Ozone Layer (1989 to present), Minamata Convention on Mercury (2009 to 2015), the Asia-Pacific Partnership on Clean Development and Climate (2006 to 2011), the Stockholm Convention on Persistent Organic Pollutants (2004 to 2015), and
Wiley protocol at separate times throughout the period. The protocol is promoted as differing from conventional hormone replacement therapy in several ways: The protocol also includes a follow-up program to monitor the serum of the bioidentical hormones. Wiley has stated that in her opinion, the most important aspect of the protocol is the specific schedule and levels of the hormone doses rather than their bioidentical nature. A patent was granted for the protocol in 2011 for the specific blend of hormones and dosing method. Concerns have been raised that serum levels may not be an acceptable marker for transdermally administered hormones, that